410 related articles for article (PubMed ID: 32528403)
61. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes.
Zilberberg E; Haas J; Dar S; Kedem A; Machtinger R; Orvieto R
Gynecol Endocrinol; 2015 Feb; 31(2):145-7. PubMed ID: 25385007
[TBL] [Abstract][Full Text] [Related]
62. GnRH Agonist and hCG (Dual Trigger) Versus hCG Trigger for Final Oocyte Maturation in Expected Normal Responders With a High Immature Oocyte Rate: Study Protocol for a Randomized, Superiority, Parallel Group, Controlled Trial.
Yan MH; Cao JX; Hou JW; Jiang WJ; Wang DD; Sun ZG; Song JY
Front Endocrinol (Lausanne); 2022; 13():831859. PubMed ID: 35418945
[TBL] [Abstract][Full Text] [Related]
63. Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes.
Cela V; Obino MER; Alberga Y; Pinelli S; Sergiampietri C; Casarosa E; Simi G; Papini F; Artini PG
Gynecol Endocrinol; 2018 Jun; 34(6):518-523. PubMed ID: 29271274
[TBL] [Abstract][Full Text] [Related]
64. Comparison of dual trigger with combination GnRH agonist and hCG versus hCG alone trigger of oocyte maturation for normal ovarian responders.
Zhou X; Guo P; Chen X; Ye D; Liu Y; Chen S
Int J Gynaecol Obstet; 2018 Jun; 141(3):327-331. PubMed ID: 29388691
[TBL] [Abstract][Full Text] [Related]
65. In vitro fertilization stimulation protocol for normal responder patients.
Marci R; Caserta D; Lisi F; Graziano A; Soave I; Lo Monte G; Patella A; Moscarini M
Gynecol Endocrinol; 2013 Feb; 29(2):109-12. PubMed ID: 22943624
[TBL] [Abstract][Full Text] [Related]
66. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
[TBL] [Abstract][Full Text] [Related]
67. Does dehydroepiandrosterone improve pregnancy rate in women undergoing IVF/ICSI with expected poor ovarian response according to the Bologna criteria? A randomized controlled trial.
Kotb MM; Hassan AM; AwadAllah AM
Eur J Obstet Gynecol Reprod Biol; 2016 May; 200():11-5. PubMed ID: 26963897
[TBL] [Abstract][Full Text] [Related]
68. Does the estradiol level on the day of human chorionic gonadotropin administration predict the clinical outcome of controlled ovarian hyperstimulation?
Erzincan SG; Esmer AC; Baysal B
Clin Exp Obstet Gynecol; 2014; 41(6):709-12. PubMed ID: 25551969
[TBL] [Abstract][Full Text] [Related]
69. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
70. Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs.
Lin H; Li Y; Li L; Wang W; Yang D; Zhang Q
PLoS One; 2014; 9(3):e91796. PubMed ID: 24642641
[TBL] [Abstract][Full Text] [Related]
71. Menstrual cycle synchronization, ovarian stimulation, and in vitro fertilization in olive baboons (Papio anubis): a prospective randomized study.
Nyachieo A; Spiessens C; Chai DC; Mwenda JM; D'Hooghe TM
Fertil Steril; 2009 Feb; 91(2):602-10. PubMed ID: 18328482
[TBL] [Abstract][Full Text] [Related]
72. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
[TBL] [Abstract][Full Text] [Related]
73. Comparison of GnRH antagonist and agonist mini-dose long protocols in infertile cases undergoing controlled ovarian hyperstimulation.
Akin H; Kumbasar S; Sik BA; Salman S; Temur M; Cakiroglu F; Ozyurt R; Kucukbas M
Clin Exp Obstet Gynecol; 2017; 44(1):116-121. PubMed ID: 29714879
[TBL] [Abstract][Full Text] [Related]
74. GnRH antagonist versus follicular-phase single-dose GnRH agonist protocol in patients of normal ovarian responses during controlled ovarian stimulation.
Geng Y; Xun Y; Hu S; Lai Q; Jin L
Gynecol Endocrinol; 2019 Apr; 35(4):309-313. PubMed ID: 30430883
[TBL] [Abstract][Full Text] [Related]
75. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study.
Bahçeci M; Ulug U; Ben-Shlomo I; Erden HF; Akman MA
J Reprod Med; 2005 Feb; 50(2):84-90. PubMed ID: 15755044
[TBL] [Abstract][Full Text] [Related]
76. Do poor-responder patients benefit from increasing the daily gonadotropin dose during controlled ovarian hyperstimulation for IVF?
Haas J; Zilberberg E; Machtinger R; Kedem A; Hourvitz A; Orvieto R
Gynecol Endocrinol; 2015 Jan; 31(1):79-82. PubMed ID: 25223892
[TBL] [Abstract][Full Text] [Related]
77. Pregnancy outcomes after controlled ovarian hyperstimulation in women with endometriosis-associated infertility: GnRH-agonist versus GnRH-antagonist.
Kolanska K; Cohen J; Bendifallah S; Selleret L; Antoine JM; Chabbert-Buffet N; Darai E; d'Argent EM
J Gynecol Obstet Hum Reprod; 2017 Nov; 46(9):681-686. PubMed ID: 28970135
[TBL] [Abstract][Full Text] [Related]
78. Live birth rate of gonadotropin-releasing hormone antagonist versus luteal phase gonadotropin-releasing hormone agonist protocol in IVF/ICSI: a systematic review and meta-analysis.
Liu C; Tian T; Lou Y; Li J; Liu P; Li R; Qiao J; Wang Y; Yang R
Expert Rev Mol Med; 2023 Dec; 26():e2. PubMed ID: 38095077
[TBL] [Abstract][Full Text] [Related]
79. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization.
Orvieto R; Zohav E; Scharf S; Rabinson J; Meltcer S; Anteby EY; Homburg R
Gynecol Endocrinol; 2007 Feb; 23(2):72-5. PubMed ID: 17454155
[TBL] [Abstract][Full Text] [Related]
80. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
